- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Microfluidics International Corporation (OTCBB: MFLU) today reported financial results for the third quarter of 2008. In addition, in a separate release issued on November 14, 2008, the Company announced that it secured a $5.0 million convertible debt financing.
-- Secured $5.0 million via a convertible debenture to support strategic
growth and path to profitability
-- Surpassed the Company's annual sales projections for its newest product,
the M-110P Microfluidizer(R) high shear fluid processor
-- Appointed Dr. Mimi Panagiotou to the position of Chief Technology
Officer to lead the research and development of new products and the
expansion of Microfluidics Reaction Technology
-- Introduced a new service business line initiative
-- Increased the Company's presence in Europe, the Middle East and Africa
For the quarter ended September 30, 2008, the Company reported revenues of $3.5 million, an increase of 52% from $2.3 million for the third quarter of 2007 and an EBITDA loss of $931,000 or $0.09 per share for the third quarter of 2008 compared to an EBITDA loss of $827,000 or $0.08 per share for the same period in 2007.
Net loss for the third quarter 2008 was $1.1 million or $0.10 per share compared to a net loss of $859,000 or $0.08 per share for the third quarter 2007.
"During my first year at Microfluidics, I have learned that the opportunity driven by our proprietary technology is even greater than I thought when I first joined the Company," said Michael C. Ferrara, President and Chief Executive Officer. "To fully capture this potential we undertook a complete restructuring of Microfluidics and have made significant improvements in all aspects of our business including but not limited to technologic refinements, quality control and reengineering the sales and marketing process. Our operating efficiencies have resulted in a foundation for improved customer satisfaction and quality and importantly, revenue growth. Combined with Friday's announcement of a significant financing, we believe, subject to our continuing assessment of the global economic conditions, we have built a business poised for growth and profitability in 2009."
"Our EBITDA loss for the third quarter was greater than expected due to a delay in shipping a significant, large production machine," said Brian E. LeClair, Executive Vice President and Chief Financial Officer. "This business will always be subject to the timing of revenue generated by our large production machines, but over the last year, we have built a solid foundation to leverage the growth of Microfluidics. The $5.0 million financing we announced last week will further support this growth and a path to profitability."
Microfluidics International Corporation will host a webcast on Tuesday, November 18, 2008 at 8:30 a.m. Eastern Time to review the financial results and to outline progress on key 2008 strategic initiatives. Participants are invited to attend the call by visiting www.mficcorp.com and clicking on the webcast link in the Investors, Events section or by dialing 800-329-9097 (within the United States) or 617-614-4929 (outside the United States). The passcode for participants is 12241634. A replay will be available approximately two hours after the live call through November 21, 2008. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode for participants is 51388614. A replay will also be posted on the Company's website approximately two hours after the live call and will be available for a period of 30 days.
About Microfluidics International Corporation
Microfluidics International Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical and cosmetics industries. Microfluidics International Corporation applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.
The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics International Corporation equipment customers.
Safe Harbor for Forward-Looking Statements
Certain statements in this press release contain "forward-looking statements." All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including the section of this press release entitled "Outlook"; any projections of earnings, revenue or other financial items relating to the Company, any statement of the plans, strategies and objectives of management for future operations; any statements concerning proposed future growth rates in the markets we serve; any statements of belief; any characterization of and the Company's ability to control contingent liabilities; anticipated trends in the Company's businesses; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words "may," "estimate," "intend," "continue," "believe," "expect," "anticipate," and other similar words. Although the Company believes that the expectations reflected in any forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties beyond the control of the Company. These risks and uncertainties include, but are not limited to, risks and uncertainties relating to general economic conditions, geopolitical factors, future levels of general industrial manufacturing activity, future financial performance, market acceptance of new or enhanced versions of the Company's products, the pricing of raw materials, changes in the competitive environments in which the Company's businesses operate, the outcome of pending or future litigation and governmental proceedings and approvals, estimated legal costs, increases in interest rates, the Company's ability to meet its debt obligations, and risks and uncertainties listed or disclosed in the Company's reports filed with the Securities and Exchange Commission, including, without limitation, the risks identified under the heading "Risk Factors" set forth in the Company's Annual Report filed on Form 10-K. The Company does not intend, and undertakes no obligation, to update or alter any forward-looking statements.
EBITDA and Non-GAAP Measures
In addition to the results reported in accordance with generally accepted accounting standards (GAAP) within this release, the Company may reference certain information that is considered a non-GAAP financial measure. Management believes these measures are useful and relevant to management and investors in their analysis of the Company's underlying business and operating performance. Management also uses this information for operational planning and decision-making purposes. Non-GAAP financial measures should not be considered a substitute for any GAAP measures. Additionally, non-GAAP measures as presented by the Company may not be comparable to similarly titled measures reported by other companies. One specific non-GAAP measure used by the Company is "EBITDA", which is defined as earnings before interest, taxes, depreciation and amortization. Management utilizes the line item non-GAAP operations statement for operational planning and decision-making purposes. A reconciliation of GAAP to non-GAAP financial information discussed in this release is contained in the attached exhibits.
MICROFLUIDICS INTERNATIONAL CORPORATION Condensed Consolidated Statements of Operations (Unaudited - in thousands, except share and per share amounts) For The Three Months Ended For The Nine Months Ended September 30, September 30, 2008 2007 2008 2007 Revenues $ 3,511 $ 2,311 $ 11,407 $ 8,670 Cost of goods 1,708 1,118 5,542 3,765 sold Gross profit 1,803 1,193 5,865 4,905 Operating expenses: Research and 569 436 1,631 1,411 development Selling 1,199 840 3,327 2,649 General and 1,057 784 3,174 2,267 administrative Total operating 2,825 2,060 8,132 6,327 expenses Loss from (1,022 ) (867 ) (2,267 ) (1,422 ) operations Interest expense (39 ) (7 ) (50 ) (15 ) Interest income - 15 21 53 Net loss $ (1,061 ) $ (859 ) $ (2,296 ) $ (1,384 ) Net loss per common share: Basic $ (0.10 ) $ (0.08 ) $ (0.22 ) $ (0.14 ) Diluted $ (0.10 ) $ (0.08 ) $ (0.22 ) $ (0.14 ) Weighted average number of common and common equivalent shares outstanding: Basic 10,299,938 10,203,257 10,278,633 10,168,198 Diluted 10,299,938 10,203,257 10,278,633 10,168,198 MICROFLUIDICS INTERNATIONAL CORPORATION Condensed Consolidated Balance Sheets (Unaudited - in thousands, except share and per share amounts) September 30, December 31, 2008 2007 ASSETS Current assets: Cash and cash equivalents $ 557 $ 756 Accounts receivable, net of allowance of $41 both 2,913 2,582 at September 30, 2008 and December 31, 2007 Inventories 2,668 2,353 Prepaid and other current assets 721 281 Total current assets 6,859 5,972 Property and equipment, net 967 325 Patents and licenses, net 56 60 Total assets $ 7,882 $ 6,357 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Revolving credit line $ 1,999 $ 262 Current maturities of long-term debt and 8 65 obligations under capital lease Accounts payable 1,949 129 Accrued expenses 836 725 Customer advances 386 409 Total current liabilities 5,178 1,590 Total liabilities 5,178 1,590 Stockholders' equity: Common stock; $.01 par value; 20,000,000 shares authorized; 10,580,978 and 10,517,178 shares issued; 10,345,532 and 10,256,732 shares 106 105 outstanding as of September 30, 2008 and December 31, 2007, respectively. Additional paid-in capital 17,591 17,378 Accumulated deficit (14,324 ) (12,028 ) Treasury stock, 235,446 and 260,446 shares, at cost, as of September 30, 2008 and December 31, (669 ) (688 ) 2007, respectively. Total stockholders' equity 2,704 4,767 Total liabilities and stockholders' equity $ 7,882 $ 6,357 MICROFLUIDICS INTERNATIONAL CORPORATION U.S. GAAP TO Non-GAAP Measure Reconciliations and Earnings Before Interest, Taxes, Depreciation and Amortization ( EBITDA) ( In thousands, except share and per share amounts) For The Three Months Ended For The Nine Months Ended September 30, September 30, 2008 2007 2008 2007 Net loss $ (1,061 ) $ (859 ) $ (2,296 ) $ (1,384 ) Net interest 39 (8 ) 29 (38 ) expense (income) Depreciation and 91 40 174 122 amortization EBITDA ( Non-GAAP $ (931 ) $ (827 ) $ (2,093 ) $ (1,300 ) Measure) Weighted average number of common and common equivalent shares outstanding: Basic: 10,299,938 10,203,257 10,278,633 10,168,198 Diluted: 10,299,938 10,203,257 10,278,633 10,168,198 EBITDA per common share (Non-GAAP Measure): Basic: $ (0.09 ) $ (0.08 ) $ (0.20 ) $ (0.13 ) Diluted: $ (0.09 ) $ (0.08 ) $ (0.20 ) $ (0.13 )
For more information, please click here
Microfluidics International Corporation
Brian E. LeClair
MacDougall Biomedical Communications
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Soft decoupling of organic molecules on metal June 23rd, 2016
Droplets finally all the same size -- in a nanodroplet library June 20th, 2016
Soft decoupling of organic molecules on metal June 23rd, 2016
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016